CannPal Animal Therapeutics (ASX: CP1)


CannPal Animal Therapeutics (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals. www.cannpal.com

CannPal Animal Therapeutics ASX CP1 CSIRO MicroMAX Commonwealth Scientific and Industrial Research Organisation cannabis

CannPal secures commercial rights to CSIRO’s MicroMAX technology

Following an 18 month review, CannPal (ASX: CP1) has secured exclusive rights to commercialise the Commonwealth Scientific...
CannPal Animal Therapeutics ASX CP1 veterinary research University of Melbourne

CannPal Animal Therapeutics to conduct veterinary research alongside the University of Melbourne

CannPal Animal Therapeutics (ASX: CP1) is looking to develop and broaden its research pipeline after announcing that...
CannPal Animal Therapeutics ASX CP1 CSIRO research cannabinoid medications

CannPal and CSIRO to advance cannabinoid medicines for pets

Animal health company CannPal Animal Therapeutics (ASX: CP1) has entered into a research agreement with the Commonwealth...
CannPal ASX CP1 secures Australian cannabis import licence research CPAT-01

CannPal secures Australian cannabis import licence to bring in formulations for research

CannPal Animal Therapeutics (ASX: CP1) has secured its import licence from the Australian Government’s Office of Drug Control,...
CannPal Animal Therapeutics ASX CP1 NSW government approval cannabis trial dogs

Debutant ‘pot stock’ CannPal gains NSW Govt approval for cannabis-based trials in dogs

The New South Wales Department of Health has approved CannPal Animal Therapeutics’ (ASX: CP1) application to possess...